Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Restoring Insulin Secretion Pediatric Medication Study

Trial Profile

Restoring Insulin Secretion Pediatric Medication Study

Phase of Trial: Phase III

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Insulin glargine (Primary) ; Metformin (Primary)
  • Indications Prediabetic-state; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms RISE Peds
  • Most Recent Events

    • 01 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 25 Jun 2018 Primary endpoint (B-cell function measured by hyperglycemic clamp techniques: clamp-derived steady-state C-peptide and ACPRmax at 15 months (both evaluated jointly with M/I; co-primary outcomes)) has not been met, according to results published in the Diabetes Care Journal.
    • 25 Jun 2018 According to results published in the Diabetes Care Journal, this trial was trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top